Malaria vaccine Mosquirix all you need to know!
The World health Organization (WHO) has authorised the world's first malaria vaccine, RTS,S/AS01, also known by the commercial name Mosquirix. More than 400,000 people die each year from mosquito-borne illness, the majority of whom are African children. GlaxoSmithKline, a british pharmaceutical company, created the Mosquirix vaccine.
WHO Director-General Tedros Adhanom Ghebreyesus said they are really proud of this vaccination since it was created in Africa by African scientists. In 2019, the vaccine was distributed in over two million doses in Kenya, Ghana, and malawi as part of a trial programme.
Malaria kills a kid every two minutes on the African continent. GlaxoSmithKline, a british pharmaceutical company, developed the vaccine for the first time in 1987.
Mosquirix is a malaria-prevention vaccination for children aged 6 weeks to 17 months. The Mosquirix vaccination also protects against hepatitis B virus infection of the liver. However, according to the european Medicines Agency, the vaccination should not be used only for this reason.
GlaxoSmithKline developed the vaccine in 1987. It does, however, confront difficulties. The Mosquirix vaccination can take up to four doses to work, and the protection lasts just a few months. 18 months following the third injection, a fourth injection is suggested. Mosquirix is only available with a doctor's prescription.
Mosquirix's active ingredient is made up of proteins discovered on the Plasmodium falciparum parasite's surdata-face. When a kid is exposed to the parasite, the immune system identifies the 'foreign' proteins and produces antibodies against them.
WHO Director-General Tedros Adhanom Ghebreyesus said they are really proud of this vaccination since it was created in Africa by African scientists. In 2019, the vaccine was distributed in over two million doses in Kenya, Ghana, and malawi as part of a trial programme.
Malaria kills a kid every two minutes on the African continent. GlaxoSmithKline, a british pharmaceutical company, developed the vaccine for the first time in 1987.
Mosquirix is a malaria-prevention vaccination for children aged 6 weeks to 17 months. The Mosquirix vaccination also protects against hepatitis B virus infection of the liver. However, according to the european Medicines Agency, the vaccination should not be used only for this reason.
GlaxoSmithKline developed the vaccine in 1987. It does, however, confront difficulties. The Mosquirix vaccination can take up to four doses to work, and the protection lasts just a few months. 18 months following the third injection, a fourth injection is suggested. Mosquirix is only available with a doctor's prescription.
Mosquirix's active ingredient is made up of proteins discovered on the Plasmodium falciparum parasite's surdata-face. When a kid is exposed to the parasite, the immune system identifies the 'foreign' proteins and produces antibodies against them.